GeoVax Labs Inc, known by its ticker symbol as GOVX, is a pioneering biotechnology company in the field of vaccines and immunotherapies. The company is primarily focused on developing, testing and commercializing superior vaccines that prevent or control various infectious diseases including HIV, Zika, Hepatitis B, and hemorrhagic fevers like Ebola, as well as certain types of cancer. GeoVax Labs is headquartered in Smyrna, Georgia, USA.
Founded in 2001, GeoVax Labs uses a unique approach to vaccine development that utilizes recombinant DNA technology to create the most effective vaccines for serious communicable diseases. The company's vaccine candidates are of two types - Modified Vaccinia Ankara, or MVA, vector and another based on a proprietary liposome-enveloped virus-like particle (VLP).
GeoVax Lab's HIV vaccine was the first of its kind to progress to phase II clinical trials and has shown promising results in both preventing and treating HIV. Similarly, their Ebola and Zika vaccines have also shown significant efficacy in animal trials.
In 2020, aiming to combat the global COVID-19 pandemic, GeoVax Labs turned its attention toward developing a vaccine to fight the virus. The company's expertise in creating vaccines for infectious diseases poised them to make significant contributions to the global fight against the pandemic.
Since its founding, GeoVax Labs has received several grants and contracts from both national and international organizations like National Institutes of Health (NIH), U.S. Department of Defense (DoD), National Institute of Allergy and Infectious Diseases (NIAID), and the World Health Organization (WHO). These significant recognitions and funding greatly validate the potential of GeoVax's technology and products, reflecting their national and global importance.
In the stock market, GOVX has received significant attention from investors due to its remarkable R&D accomplishments and its increasingly relevant role as a biotech entity amid the pandemic era.
Overall, GeoVax Labs Inc plays a pivotal role in the global efforts to protect against infectious diseases, making significant contributions to public health and biomedical research. The company's relentless commitment to creating efficient vaccines and furthering our understanding of serious health threats makes it a valuable player in today's healthcare landscape.